What is the KDPI?

The Kidney Donor Profile Index (KDPI) is a numerical measure that combines ten donor factors, including clinical parameters and demographics, to summarize into a single number the quality of deceased donor kidneys relative to other recovered kidneys. The KDPI is derived by first calculating the Kidney Donor Risk Index (KDRI) for a deceased donor.

Kidneys from a donor with a KDPI of 90%, for example, have a KDRI (which indicates relative risk of graft failure) greater than 90% of recovered kidneys. The KDPI is simply a mapping of the KDRI from a relative risk scale to a cumulative percentage scale. The reference population used for this mapping is all deceased donors in the United States with a kidney recovered for the purpose of transplantation in the prior calendar year. Lower KDPI values are associated with increased donor quality and expected longevity.

What is the KDRI?

The Kidney Donor Risk Index (KDRI) is an estimate of the relative risk of post-transplant kidney graft failure (in an average, adult recipient) from a particular deceased donor compared to a reference donor. The reference donor chosen in the original KDRI publication was age 40, non-diabetic, etc. The median (50th percentile) donor was chosen as the reference donor to produce the scaled (or “normalized”) version of KDRI displayed in DonorNet®. A donor with a scaled KDRI of 1.28, for example, confers an estimated risk of kidney graft failure that is 1.28 times that of the median donor. Lower KDRI values are associated with increased donor quality and expected longevity.

Figure 1. Kaplan–Meier Graft Survival Estimates for Adult, Deceased Donor, Kidney–Alone Transplants During 2006–2016, by KDPI

Based on OPTN data as of April 20, 2018.
When performing a retrospective analysis of donors for publication, which should I use: Scaled KDRI (normalized relative to the median donor), Original KDRI (per Rao), or KDPI?

The normalized version of KDRI that is displayed in DonorNet® is expressed relative to the median donor recovered last year to improve interpretation and aid in real-time, organ-offer decision-making. However, it is not necessary to use the normalized version of KDRI for published research. The original KDRI, either including or excluding non-donor factors, can still be used. KDPI may also be an informative way to express relative donor quality in published research. Whichever approach is used, the publication should clearly articulate:

(a) whether or not the KDRI included non-donor factors,
(b) what reference donor was used for KDRI, and
(c) which reference population was chosen for mapping KDRI to KDPI (if applicable).

What are some intended uses of the KDPI?

The primary purpose of adding KDPI to DonorNet® is for implementation of the “longevity matching” concept into the kidney allocation system. Candidates with longer estimated post-transplant longevity (EPTS score of 20% or less) receive priority for kidneys from donors with KDPI of 20%.

The KDPI also provides a measure of donor quality for assisting transplant professionals in evaluating the suitability of deceased donor kidney offers for each of their candidates. Just as some candidates are more likely to benefit from an ECD kidney than others, transplant clinicians may choose to accept high-KDPI kidneys, depending on the medical circumstances of each particular candidate and expected center-specific waiting times.

KDPI may also be useful in determining whether to accept an offer of both kidneys from a particular donor or to decline if only a single kidney is available. For example, a program may be willing to consider accepting kidneys from a donor with an elevated KDPI, but only if both kidneys are available (per OPTN Policy 8.6: Double Kidney Allocation) and would together provide sufficient renal mass for an anticipated successful outcome.

Calculating and Interpreting the Kidney Donor Risk Index (KDRI)

The KDPI is derived from the Kidney Donor Risk Index (KDRI)¹. Consequently, to determine a donor’s KDPI, the first step is to calculate the donor’s KDRI.

The KDPI displayed in DonorNet® and referenced in this document is the scaled, donor-only version of the KDRI. As explained in Rao, et al¹, several factors pertaining to the recipient and/or transplant procedure (cold ischemic time, degree of HLA mismatching, single vs. double vs. en-bloc kidneys) can also be used to calculate a “full” KDRI.

Since these factors are generally not known at the time offers are made or are candidate-specific, the donor-only KDRI was implemented.

The following donor characteristics are used to calculate the KDRI:

- ✓ Age
- ✓ Height
- ✓ Weight
- ✓ Ethnicity
- ✓ History of Hypertension
- ✓ History of Diabetes
- ✓ Cause of Death
- ✓ Serum Creatinine
- ✓ Hepatitis C Virus (HCV) Status, from serological or NAT testing
- ✓ Donation after Circulatory Death (DCD) Status

The association between these donor factors and graft survival was determined by Rao, et al¹, by estimating a multivariable Cox proportional hazards regression model using graft outcomes from nearly 70,000 adult, solitary, first-time deceased donor kidney recipients in the United States from 1995-2005. The estimated coefficients derived from this model are shown in Table 1.
Table 1. KDRI Donor Factors and Model Coefficients

<table>
<thead>
<tr>
<th>Donor Characteristic</th>
<th>Applies to Which Donors</th>
<th>KDRI Coefficient (β)</th>
<th>KDRI Xβ Component</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (integer years)</td>
<td>All</td>
<td>0.0128</td>
<td>0.0128*(Age–40)</td>
</tr>
<tr>
<td></td>
<td>Age &lt; 18</td>
<td>-0.0194</td>
<td>-0.0194*(Age–18)</td>
</tr>
<tr>
<td></td>
<td>Age &gt; 50</td>
<td>0.0107</td>
<td>0.0107*(Age–50)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>All</td>
<td>-0.0464</td>
<td>-0.0464*(Hgt–170)/10</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>Weight &lt; 80 kg</td>
<td>-0.0199</td>
<td>-0.0199*(Wgt–80)/5</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>African American</td>
<td>0.1790</td>
<td>0.1790</td>
</tr>
<tr>
<td>History of Hypertension</td>
<td>Hypertensive</td>
<td>0.1260</td>
<td>0.1260</td>
</tr>
<tr>
<td>History of Diabetes</td>
<td>Diabetic</td>
<td>0.1300</td>
<td>0.1300</td>
</tr>
<tr>
<td>Cause of Death</td>
<td>Cause of Death: CVA</td>
<td>0.0881</td>
<td>0.0881</td>
</tr>
<tr>
<td>Serum Creatinine (mg/dL)</td>
<td>All</td>
<td>0.2200</td>
<td>0.2200*(Creat–1)</td>
</tr>
<tr>
<td></td>
<td>Creatinine &gt; 1.5</td>
<td>-0.2090</td>
<td>-0.2090*(Creat–1.5)</td>
</tr>
<tr>
<td>HCV Status</td>
<td>HCV Positive †</td>
<td>0.2400</td>
<td>0.2400</td>
</tr>
<tr>
<td>DCD Status</td>
<td>DCD</td>
<td>0.1330</td>
<td>0.1330</td>
</tr>
</tbody>
</table>

† Donors are considered HCV positive if either serological or NAT results are positive.

The KDRI is calculated for a particular donor by summing the $X\beta$ components for all applicable donor characteristics, then applying the antilog function (base $e$) to this sum as follows:

$$X\beta = \sum \text{KDRI score components}$$

$$\text{KDRI}_{\text{RAO}} = e^{X\beta}$$

$\text{KDRI}_{\text{RAO}}$ is interpreted as the relative risk of post-transplant graft failure for this donor compared to a reference donor (age=40 years, non-African American, etc.) as defined in Rao, et al\textsuperscript{1}. This particular reference donor is neither an “ideal” donor nor an “average” donor, but somewhere in between. Consequently, to aid in its interpretation, the version of the KDRI displayed in DonorNet\textsuperscript{®} is normalized (or “scaled”) such that a value of 1.0 corresponds to the median donor as follows:

$$\text{KDRI}_{\text{MEDIAN}} = \frac{\text{KDRI}_{\text{RAO}}}{\text{scaling factor}}$$

The “scaling factor” is the median $\text{KDRI}_{\text{RAO}}$ value among all kidney donors recovered during the previous calendar year. This value was 1.20659821120231 in 2016; the scaling factor currently in use can be found at the bottom of the KDRI-to-KDPI Mapping Table document located on the OPTN website. The use of this scaling factor does not affect the KDPI nor the donor’s rank-ordering relative to other donors.

The $\text{KDRI}_{\text{MEDIAN}}$ is interpreted as the relative risk of post-transplant graft failure (in an average, adult recipient) for this donor compared to the median kidney donor recovered last year. For example a donor with KDPI=74%, “The estimated risk of kidney graft failure from this donor is higher than 74% of all kidney donors recovered in 2016 and 1.53 times that of the median donor from 2016”. The value of 1.53 is the scaled KDRI.

As shown in Figure 2, in 2016 $\text{KDRI}_{\text{RAO}}$ ranged from 0.62 to 4, and $\text{KDRI}_{\text{MEDIAN}}$ ranged from 0.51 to 3.32.
Calculating and Interpreting the Kidney Donor Profile Index (KDPI)

The KDPI is simply a mapping of the KDRI, a measure of relative risk, to a cumulative percentage scale. The KDPI is calculated to the nearest integer percentage value and ranges from 0% to 100%. A donor with KDPI of 0% has a KDRI less than all donors in the reference population. In general, a donor with a KDPI of X% implies that the donor's KDRI exceeds more than \((X - 1)\%\), but not more than X%, of all donors in the reference population. For example:

- A donor with a KDPI of 20% has a KDRI exceeding at least 19% and at most 20% of all donors in the reference population.
- A donor with a KDPI of 99% has a KDRI exceeding at least 98% and at most 99% of all donors in the reference population.
- A donor with a KDPI of 100% has a KDRI exceeding more than 99% of all donors in the reference population, including donors with KDRI exceeding the maximum observed value in the reference population.

The KDRI-to-KDPI Mapping Table, located on the OPTN website, shows the KDPI associated with every possible KDRI\text{MEDIAN} value.
Example Calculation: KDRI and KDPI

Calculate the KDRI and KDPI for a donor with the following characteristics:

- Age: 52 years
- Height: 5’11” (183 cm)
- Weight: 177 lb (81 kg)
- Ethnicity: Hispanic/Latino
- History of Hypertension: Yes, donor has history of hypertension
- Diabetes Status: No, donor has no history of diabetes
- Cause of Death (COD): Cerebrovascular accident (CVA)
- Serum Creatinine: 1.7 mg/dL
- HCV Status: Negative
- DCD Status: Yes, donor was recovered as a DCD

Recall the formula for calculating $X_{\beta}$ from page 3:

$$X_{\beta} = 0.0128 \times (age - 40) - 0.0194 \times (age - 18) \times \mathbb{I}(age < 18) + 0.0107 \times (age - 50) \times \mathbb{I}(age > 50)$$

$$- 0.0464 \times \left( \frac{height - 170}{10} \right) - 0.0199 \times \left( \frac{weight - 80}{5} \right) \times \mathbb{I}(weight < 80 \text{ kg})$$

$$+ 0.1790 \times \mathbb{I}(\text{African American ethnicity}) + 0.1260 \times \mathbb{I}(\text{History of hypertension}) + 0.1300 \times \mathbb{I}(\text{History of diabetes})$$

$$+ 0.0881 \times \mathbb{I}(\text{COD} = \text{CVA}) + 0.2200 \times (\text{Creatinine} - 1)$$

$$- 0.2090 \times (\text{Creatinine} - 1) \times \mathbb{I}(\text{Creatinine} > 1.5 \text{ mg/dL}) + 0.2400 \times \mathbb{I}(\text{HCV positive}) + 0.1330 \times \mathbb{I}(\text{DCD})$$

First, calculate and take the sum of each $X_{\beta}$ component:

$$X_{\beta} = \left[ 0.0128 \times (52 - 40) - 0.0194 \times (52 - 18) \times 0 + 0.0107 \times (52 - 50) \times 1 \right]$$

$$- \left[ 0.0464 \times \frac{183 - 170}{10} \right] - \left[ 0.0199 \times \frac{81 - 80}{5} \times 0 \right]$$

$$+ \left[ 0.1790 \times 0 \right] + \left[ 0.1260 \times 1 \right] + \left[ 0.1300 \times 0 \right]$$

$$+ \left[ 0.0881 \times 1 \right] + \left[ 0.2200 \times (1.7 - 1) - 0.2090 \times (1.7 - 1.5) \times 1 \right]$$

$$+ \left[ 0.2400 \times 0 \right] + \left[ 0.1330 \times 1 \right]$$

$$= 0.57398000000000$$

Next, exponentiate, as follows:

$$KDRI_{RAO} = e^{X_{\beta}} = e^{0.57398000000000} = 1.77531877792565$$

Next, divide this donor’s KDRI_{RAO} by the median KDRI_{RAO} in 2016 (or most recent cohort):

$$KDRI_{MEDIAN} = \frac{1.77531877792565}{1.20659821120231} = 1.47134212652001$$
Next, find the KDPI corresponding to a \( KDRI_{\text{MEDIAN}} \) of 1.47134212652001 on the KDRI-to-KDPI Mapping Table from 2016 (or most recent cohort):

\[
\text{KDPI} = 70\
\]

Interpretation: The estimated risk of kidney graft failure from this donor is higher than 70% of kidney donors recovered in 2016 and 1.47 times that of the median donor recovered in 2016.

**Frequently Asked Questions (FAQ) about KDPI**

**How strong is the association between KDRI/KDPI and graft survival?**

*Figure 1* shows that as KDPI increases, the expected graft survival decreases substantially, on average, based on the population of primary, adult, deceased donor, kidney alone transplants from 2006-2016. This analysis was not adjusted for recipient factors. The strength of the association between KDPI and graft survival changes very little when adjusting for recipient factors in a multivariable model.

The predictive power of the KDPI can be summarized into a single number, the c-statistic, which is approximately 0.60. The c-statistic ranges from 0.5 to 1.0, with higher values indicating greater discriminatory power (the ability to separate more successful from less unsuccessful graft outcomes along the KDPI scale). A c-statistic of 0.60 is considered to be only moderately predictive, whereas values near 0.70 or 0.80+ are more desirable and indicative of models with high discriminatory power.

Graft outcome is affected not only by donor characteristics, but also by recipient variables, factors related to the transplant procedure, as well as by the transplant program itself. KDPI is designed only to capture the donor factors that are predictive of graft outcome. Transplant outcomes are also affected by other factors not included in the KDPI, such as recipient age, diagnosis, and transplant program performance. A model that accounts for these additional sources of variation would result in a somewhat higher c-statistic. However, the goal of the KDRI is strictly to summarize graft failure risk based on differential characteristics of a deceased donor, not to explain all sources of variation in kidney transplant outcomes.

The KDPI has effectively the same predictive power as the KDRI, with only a trivial difference induced by the use of the discrete (one percentage point intervals) mapping table.

Survival rate estimates in Table 2 are based on a Cox regression model with \( \log(\text{KDRI}) \) as the sole independent variable, which allowed estimation of survival at desired values of KDPI, and graft failure defined as loss of graft or patient death. These survival rates are for single kidney alone transplants; survival rates are generally higher for en-bloc or double kidney transplants. These rates were not adjusted for recipient characteristics, but instead reflect the expected survival averaged across the broad spectrum of adult recipients.

**How much predictive power is lost when using the donor-only version of the KDRI compared to the “full” KDRI that contains recipient-donor matching and transplant factors?**

Virtually no predictive ability is lost by using a donor-only version of the KDRI \( (c = 0.596) \) compared to a full version of the KDRI \( (c = 0.601) \) that includes the degree of HLA matching, cold ischemic time, and transplant procedure type (single vs. double vs. en-bloc)\(^5\). However, survival rates tend to be substantially higher for en bloc transplants compared to single kidney transplants, all else equal. Additionally, dual kidney transplants confer longer expected survival, especially for high KDPI kidneys\(^4\).

**What other donor factors were considered for possible inclusion in the KDRI/KDPI?**

Donor factors evaluated but not explicitly included in the KDRI formula included gender and cigarette use\(^1\). Since these two characteristics were included in the multivariable modeling process, but given the other factors in the model were not statistically significant, donor gender and cigarette use can be thought of as being implicitly included in the KDRI with a model coefficient of zero.
Table 2. Estimated Kidney Graft Survival Rates for Single Kidney Transplants in the U.S. in 2016, by KDPI

<table>
<thead>
<tr>
<th>KDPI</th>
<th>KDRI_{RAO}^*</th>
<th>KDRI_{MEDIAN}^*</th>
<th>Estimated Single Kidney Graft Survival Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 Year</td>
</tr>
<tr>
<td>1%</td>
<td>0.70</td>
<td>0.58</td>
<td>97.1%</td>
</tr>
<tr>
<td>5%</td>
<td>0.77</td>
<td>0.64</td>
<td>95.7%</td>
</tr>
<tr>
<td>10%</td>
<td>0.83</td>
<td>0.68</td>
<td>96.6%</td>
</tr>
<tr>
<td>20%</td>
<td>0.92</td>
<td>0.76</td>
<td>96.6%</td>
</tr>
<tr>
<td>30%</td>
<td>1.00</td>
<td>0.83</td>
<td>95.8%</td>
</tr>
<tr>
<td>40%</td>
<td>1.10</td>
<td>0.91</td>
<td>94.4%</td>
</tr>
<tr>
<td>50%</td>
<td>1.22</td>
<td>1.00</td>
<td>94.5%</td>
</tr>
<tr>
<td>60%</td>
<td>1.35</td>
<td>1.11</td>
<td>93.3%</td>
</tr>
<tr>
<td>70%</td>
<td>1.49</td>
<td>1.22</td>
<td>93.1%</td>
</tr>
<tr>
<td>80%</td>
<td>1.67</td>
<td>1.37</td>
<td>90.1%</td>
</tr>
<tr>
<td>90%</td>
<td>1.94</td>
<td>1.61</td>
<td>87.5%</td>
</tr>
<tr>
<td>95%</td>
<td>2.24</td>
<td>1.84</td>
<td>88.7%</td>
</tr>
<tr>
<td>99%</td>
<td>2.65</td>
<td>2.19</td>
<td>82.9%</td>
</tr>
</tbody>
</table>

* Maximum of the range of KDRI rounded to 2 decimal places.


*Based on OPTN data including primary, adult, deceased donor, kidney alone transplants, as of April 20, 2018.

Is it okay to use the KDRI/KDPI as a measure of donor quality for non-renal organs?

The KDRI and KDPI were developed strictly in the context of predicting kidney graft survival. A Liver Donor Risk Index (LDRI) has been developed to summarize the quality of liver donors; similarly, a Pancreas Donor Risk Index (PDRI) exists for pancreas donors. Ideally, these organ-specific metrics should be used to aid in organ-specific decision-making.

However, it has been shown that the KDRI is highly correlated with both the LDRI and PDRI, and provides nearly identical discriminatory power (as measured by the c-statistic) as those organ-specific models. The KDRI was also shown to have only very modest discriminatory power ($c = 0.54$) for heart transplant outcomes and very little association with lung transplant outcomes ($c = 0.52$).

Though ideally the organ-specific indices should be used, it is not unreasonable to use the KDPI as an approximate measure of donor quality for livers and pancreata, and possibly even hearts.

What are the benefits of the KDPI?

KDPI is an improvement over the Expanded Criteria (ECD)/Standard Criteria Donor (SCD) dichotomy in several ways:

- KDPI incorporates 10 donor factors (instead of 4 as in the ECD definition) and is a more predictive measure of donor quality
- KDPI is a continuous ‘score’ instead of a binary (yes/no) indicator
- KDPI illuminates the fact that not all ECDs are alike:
  - Some ECD kidneys have reasonably good estimated quality
  - Some SCD kidneys actually have lower estimated quality than some ECDs
How should KDPI not be used?

The KDPI should not be turned into a dichotomous indicator such that all kidneys with a KDPI ≤ X% are considered equally “good” and those with KDPI > X% are equally “bad”. Doing so would negate one of the advantages this continuous-scale metric has over the ECD indicator.

Also, factors already included in the KDPI formula, for example, history of hypertension, should generally not be used to differentiate the quality (in terms of expected graft survival) of kidney donors with the same KDPI. As an illustration, if two donors have a KDPI of 40%, but one has a history of hypertension and the other does not, the donor with the history of hypertension should not be considered to have a significantly lower expected graft survival, since the multivariable KDRI model has already taken hypertension into account. Other clinical reasons may make a hypertensive (or diabetic, DCD, etc.) donor less preferable compared to a non-hypertensive donor, however.

Finally, though a transplant program may choose to “rule out” all kidneys with KDPI exceeding a certain threshold (either for all of their candidates or by using candidate-specific thresholds), the KDPI should never be used in isolation to “rule-in” a kidney for transplantation. The KDPI may be clinically useful, but it has limitations, as described below.

What are the limitations of the KDPI?

As previously mentioned, the predictive power of the KDPI is only moderate (c = 0.60). It is not a precise enough tool to differentiate with high confidence the quality of kidney donors with only slight differences in KDPI. Donors on opposite ends of the KDPI spectrum can be differentiated in terms of expected graft outcomes with greater confidence.

In addition, the KDPI does not include all donor factors potentially associated with kidney graft outcomes. For example, biopsy results are not included in the KDPI, in large part because many deceased donor kidneys are not biopsied. Since the KDPI is a donor-level measure, not specific to either kidney, it also does not contain any information about anatomical damage, trauma, or abnormalities that may be associated with one of a donor’s kidneys.

Further, the KDPI provides no assessment of the likelihood of disease or malignancy transmission from a deceased donor. Even though the formula includes HCV as a factor, its inclusion was strictly due to the association of HCV positivity with (lower) graft survival. Other infectious disease test results are not incorporated into the KDPI. Also not included is whether the donor meets U.S. Public Health Service guidelines for being considered at an increased risk of disease transmission. The donor’s social history, which may reflect a higher risk of disease transmission, is also absent from the KDPI.

Finally, the KDPI was developed using graft outcomes from strictly adult transplant recipients; pediatric recipients were not included in the modeling process. Consequently, KDPI should be used with caution when assessing donor quality from the perspective of a pediatric candidate.

The KDPI should be used in conjunction with these additional sources of information to make fully informed decisions about the suitability of a kidney for a particular transplant candidate.

Does the KDRI quantify the risk of kidney graft failure within a particular time window (e.g., first 6 months after transplant)?

No. The KDRI is a relative risk measure indicating an upward or downward shift in the risk of graft failure over time (the hazard function) for this donor relative to the reference donor. Thus, the KDRI does not have an interpretation limited to any particular outcome window, such as graft survival within 3 months, 6 months, 1 year, etc.

Can the KDPI be calculated for living donors?

No. The KDPI only applies to deceased donors. However, researchers have recently developed a living donor version of the KDPI that may prove useful.8

Is the KDPI applicable to pediatric donors?

Yes. Pediatric donors were included in the original KDRI analysis1. As shown in Figure 3, very young and/or small donors, whose kidneys are generally smaller and have less renal mass, typically have high KDPI values.
How are missing, unknown, and other “ambiguous” values handled in the KDPI calculation?

If any of the 10 fields used for calculating KDRI are missing, the KDRI and KDPI are not computed. However, several fields can be “non-missing” but still be ambiguous:

- History of hypertension: unknown
- History of diabetes: unknown
- HCV status (both anti-HCV and HCV NAT): unknown, not done, indeterminate, or pending

All 10 fields used for calculating KDRI are required to run a kidney match. To ensure that when matches are run every donor has a non-missing KDPI value, ambiguous values are handled as follows:

If ‘History of hypertension = unknown’ was selected, the KDRI calculation in DonorNet® assumes that the donor has a probability of having been hypertensive equal to the proportion of donors in the reference population having a history of hypertension. In 2016, this proportion was 30.91%. In such cases, the $X\beta$ component associated with a history of hypertension is the weighted average of 0 and 0.1260, or $0 \times (1 - 0.30912681000439) + 0.1260 \times (0.30912681000439) = 0.0389$.

If ‘History of diabetes = unknown’ was selected, the KDRI calculation in DonorNet® assumes that the donor has a probability of having been diabetic equal to the proportion of donors in the reference population having a history of diabetes. In 2010, this proportion was 8.97%. In such cases, the $X\beta$ component associated with a history of diabetes is the weighted average of 0 and 0.1300, or $0 \times (1 - 0.08973233874506) + 0.1300 \times (0.08973233874506) = 0.0117$.

If ‘HCV status (from both serological and NAT testing) = unknown, not done, indeterminate, or pending’, HCV status is assumed to be negative for calculating KDRI. In such cases, the $X\beta$ component associated with HCV status is zero. DonorNet® will display a warning message indicating that the donor’s HCV status is not known but was assumed negative for calculating KDRI and KDPI.

When calculating these metrics on historical data (e.g., donor fields on the Deceased Donor Registration form) for retrospective analysis purposes, KDRI and KDPI are generally not calculated for donors with any missing and/or ambiguous data elements among the 10 fields used in these calculations.
How are extreme values of creatinine, age, height, and weight handled in the KDPI calculation?

With the implementation of KDPI into DonorNet®, this application no longer allows creatinine values to be entered that are outside of the range 0.01 to 40. Values that are between 10 and 40 may be correct but are questionable, and the system will prompt the user to double check the value to make sure it is correct before proceeding. Values greater than 8 are capped at 8 for calculating KDRI; in other words, creatinine values of 8, 9, 15, and 25 would all result in the same KDRI/KDPI, all else being equal. A note will appear under the KDPI calculation indicating the creatinine was capped at 8 for KDRI/KDPI calculations.

Donor age is restricted to be between 0 and 99 in DonorNet®. Height is limited to a maximum of 7'11" (241.3 cm), and the weight must be between 1 lb (0.454 kg) and 650 lb (294 kg).

Does the duration for which a donor had hypertension or diabetes affect the KDPI calculation?

No. The KDPI is only affected by the presence or absence of hypertension or diabetes in the donor.
References


